Milestone Pharmaceuticals (MIST) EBITDA (2018 - 2022)

Milestone Pharmaceuticals (MIST) has reported EBITDA for 5 consecutive years, with -$15.0 million the latest figure, recorded in Q3 2022.

• For the quarter ending Q3 2022, EBITDA fell 5.3% year-over-year to -$15.0 million; the trailing twelve-month figure through Sep 2022 stood at -$63.0 million (down 80.51% YoY), and the FY2021 full-year result was -$43.1 million, up 15.06% from the prior year.
• EBITDA improved to -$15.0 million in Q3 2022 per MIST's latest filing, from -$16.8 million in the prior quarter.
• Across five years, EBITDA topped out at $712000.0 in Q2 2021 and bottomed at -$18.9 million in Q4 2019.
• Historically, EBITDA has averaged -$11.5 million across 5 years, with a median of -$12.8 million in 2020.
• The sharpest annual moves came in 2021 and 2022: EBITDA surged 105.43% in 2021, then plunged 2460.39% in 2022.
• Over 5 years, EBITDA stood at -$10.1 million in 2018, then slumped by 86.92% to -$18.9 million in 2019, then surged by 53.62% to -$8.8 million in 2020, then tumbled by 93.08% to -$16.9 million in 2021, then climbed by 11.16% to -$15.0 million in 2022.
• According to Business Quant data, EBITDA over the past three periods registered -$15.0 million, -$16.8 million, and -$16.9 million for Q3 2022, Q2 2022, and Q4 2021 respectively.